Reza Beheshti Zavareh

Struggling to find qualified histotechnologists for your lab? You’re not alone. I just wrapped up a conversation with a laboratory director from the West Coast, and he shared some real challenges his lab is facing. Like many, he’s dealing with a shortage of histotechnologists. His lab currently relies on travelers, which creates significant issues: 1.) These travelers are expensive. 2.) They often lead to quality problems. There’s a lack of local talent; the pipeline just isn’t there. So, what's the solution? International recruitment. Here’s how it can transform their pathology department. Build Your Own Pipeline: Instead of waiting for new histotechnologist to relocate to the this city you can take control and bring your own. Imagine bringing in 3 to 4 motivated histotechnologists from the Philippines who are ready to contribute to your lab. Quick Turnaround: The process can move fast. As a nonprofit, this lab can get new staff in about six months. That’s efficient and effective. Cost Efficiency: By hiring international candidates, they can eliminate the need for temporary workers, reducing costs and training time. Plus, these new hires can stay for up to six years, providing stability and continuity. In summary, now you know you can utilize International recruitment not just for medical laboratory scientist but histotechnologist as well.

16

8 Comments

🎉 Big News from Illumina! 🧬 At the Association of Molecular Pathology meeting in Vancouver, Illumina introduced Version 2 of the TruSight Oncology 500 research assay, designed to: ✨ Offer faster turnaround times ✨ Reduce material use by 50% ✨ Expand genomic coverage to uncover rare cancer biomarkers 🔬 FDA-cleared TruSight Oncology Comprehensive is also now available in the U.S., enabling precision oncology with 517-gene tumor profiling. This innovation supports therapies like Bayer’s Vitrakvi and Eli Lilly and Company’s Retevmo, accelerating breakthroughs in cancer care. 🌟 #Oncology #PrecisionMedicine #CancerResearch #Genomics #Innovation

32

1 Comment

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

Sad to see the #PacBio news! They have laid off 195 employees as part of cost-cutting measures, this comes after disappointing preliminary financial results for the first quarter. "𝘝𝘪𝘳𝘵𝘶𝘢𝘭𝘭𝘺 𝘢𝘭𝘭 𝘧𝘶𝘯𝘤𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘢𝘭𝘭 𝘳𝘦𝘨𝘪𝘰𝘯𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥" 𝘸𝘦𝘳𝘦 𝘢𝘧𝘧𝘦𝘤𝘵𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘭𝘢𝘺𝘰𝘧𝘧𝘴, 𝘴𝘢𝘪𝘥 𝘊𝘌𝘖 𝘊𝘩𝘳𝘪𝘴𝘵𝘪𝘢𝘯 𝘏𝘦𝘯𝘳𝘺 In addition to the layoffs, the firm will be closing its San Diego location. If you have been affected by the recent restructuring or any others in the biotech market please reach out. We can help with 𝗖𝗩 𝘄𝗿𝗶𝘁𝗶𝗻𝗴, 𝘂𝗽𝗱𝗮𝘁𝗶𝗻𝗴 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀, 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝗮𝗱𝘃𝗶𝗰𝗲 𝗲𝘁𝗰. 𝐖𝐞 𝐡𝐚𝐯𝐞 𝐪𝐮𝐢𝐭𝐞 𝐚 𝐟𝐞𝐰 𝐯𝐚𝐜𝐚𝐧𝐜𝐢𝐞𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐄𝐮𝐫𝐨𝐩𝐞 𝐚𝐧𝐝 𝐔𝐒: 𝗨𝗦𝗔 🚚𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗟𝗼𝗴𝗶𝘀𝘁𝗶𝗰𝘀 – Washington DC – Life Sciences 🔬𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗦𝗮𝗹𝗲𝘀 – Boston – Bioanalytical Services 🔬𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗦𝗮𝗹𝗲𝘀 – San Francisco – Bioanalytical Services 🥼𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 – West Coast – Bioanalytical Drug Development 📈𝗦𝗲𝗻𝗶𝗼𝗿 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 – East Coast (Remote) – Proteomics Equipment 📈𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 – East Coast (Remote) – Proteomics consumables ⚖️𝗦𝗲𝗻𝗶𝗼𝗿 𝗣𝗮𝘁𝗲𝗻𝘁 𝗔𝗴𝗲𝗻𝘁 – San Jose – Life Science 🛠️𝗗𝗲𝗽𝗼𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 – Maryland – Life Sciences 🥼𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 – San Jose – NGS Library Prep 𝗘𝘂𝗿𝗼𝗽𝗲 🧬𝗖𝗘𝗢 – Bioinformatics - UK 🔬𝗦𝗮𝗹𝗲 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 – North UK – Proteomics Equipment 🖥️𝗦𝗮𝗹𝗲 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 – Germany – Bioinformatics 🔬𝗙𝗶𝗲𝗹𝗱 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿 – Nordics – Lab Equipment 🛠️𝗙𝗶𝗲𝗹𝗱 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿 – France – Analytical Sciences 🥼𝗙𝗶𝗲𝗹𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 – France – Analytical Sciences 🩸𝗙𝗶𝗲𝗹𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 – Germany – Biomedical Sciences 𝐈𝐟 𝐲𝐨𝐮’𝐝 𝐥𝐢𝐤𝐞 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐫𝐨𝐥𝐞𝐬 𝐨𝐫 𝐰𝐨𝐮𝐥𝐝 𝐥𝐢𝐤𝐞 𝐚𝐧𝐲 𝐚𝐝𝐯𝐢𝐜𝐞 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐯𝐢𝐚 𝐋𝐢𝐧𝐤𝐞𝐝𝐈𝐧 𝐨𝐫 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐤𝐝𝐚𝐯𝐢𝐬@𝐢𝐧𝐯𝐞𝐧𝐢𝐚𝐠𝐫𝐨𝐮𝐩.𝐜𝐨𝐦!

78

4 Comments

New trends in M&A deal breakdown, IO in this case... ... May shed lights on domestic and international BD licensing deal negotiation in 2024 too. Here is my scientific breakdown of the same deal 2 days ago...https://lnkd.in/exG464j8 Good to learn the business side of the deal. Michael Mischke-Reeds

2

Breaking barriers in ADC development: What’s next? 🔎 Antibody-drug conjugates are no longer just a concept – they’re revolutionizing cancer therapy with precision-targeted treatments. However, their success hinges on robust development strategies. Allucent explores how improved analytical methods, scalable manufacturing, and compliance with global regulatory standards are key to unlocking the full potential of ADCs. 🚀 By understanding the complex interplay of science, strategy, and regulation, biotech companies can navigate the challenges of bringing ADCs from the lab to the clinic. Dive into Allucent’s roadmap for clinical success and learn how ADCs are evolving to meet the unmet needs in oncology. 🔬 Full article below ⬇️ https://lnkd.in/dmUUXcdB #ADCtherapies #oncologyinnovation #cancerresearch #targetedtherapies #precisionmedicine #bispecificADCs #pharmabreakthroughs #drugdevelopment 

9

"San Diago... which of course in German means..." (you can fill in the blank in your head if you know the reference 😂) But I AM in gorgeous San Diego! Please reach out if you've been curious about base editing and would like to have an in person seminar in the So Cal region this month! Why base editing for your therapeutic cell engineering pipelines? ⏲️ SAVE TIME- reduce timelines on multiplex edited cell products by up to 90% 💰 SAVE ON COSTS of manufacturing when less steps are required to reach the end product 💪 HEALTHIER CELL PRODUCTS - gene editing with our platform avoids double strand DNA breaks, reducing the risk of genomic translocations, reducing cytotoxicity, and supporting normal growth rates

23

1 Comment

💰 𝐂𝐆𝐓 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐑𝐨𝐮𝐧𝐝 𝐔𝐩: 𝐐𝟑 𝟐𝟎𝟐𝟒 💰 🌱 𝗦𝗘𝗘𝗗 𝗙𝗨𝗡𝗗𝗜𝗡𝗚 🌱 🧬 Amlogenyx (Ultragenyx) raised $14 million to support the development of novel gene therapies for Alzheimer's disease and other amyloid diseases 🧬 Kano Therapeutics secured $7.1M to develop its innovative non-viral DNA insertion technology using single-stranded DNA (ssDNA). 🧬 Vironexis Biotherapeutics unveiled with $26 million to advance their AAV gene therapy pipeline taking aim at blood cancers and solid tumor metastasis prevention. 💸 𝗦𝗘𝗥𝗜𝗘𝗦 𝗔 💸 🧬 AIRNA closed $90 million to advance their RNA editing therapeutics into clinical trials and further develop their pipeline. 🦠 LIfT BioSciences raised £10 million to advance its Immunomodulatory Alpha Neutrophils (IMANs) into clinical trials. 🦠 GC Therapeutics launched with $75 million to develop next-generation cell therapies using its TFome™ platform. 🦠 Shinobi Therapeutics expanded their Series A to $119 million to support development of their immune evasive iPSC-derived technology. 💸 𝗦𝗘𝗥𝗜𝗘𝗦 𝗕 💸 🧬 Beacon Therapeutics raised $170 million to support the advancement of gene therapy programs for eye diseases. 🦠 Outpace Bio raised $144 million to advance their T cell therapies for solid tumors. 💸 𝗦𝗘𝗥𝗜𝗘𝗦 𝗖 💸 🦠 Arsenal Biosciences, Inc. raised $325 million to support the development of its programmable cell therapy programs. 💵 𝗚𝗥𝗔𝗡𝗧𝗦 💵 🧬 Rejuvenate Bio received a $4M grant to advance RJB-0402, a gene therapy for desmoplakin gene variant arrhythmogenic cardiomyopathy. 🦠 The Multiple Myeloma Research Foundation - MMRF invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies, Inc. 🧬 GENEXYS BioMed received $320,000 from the NIH to advance its non-viral delivery system for delivering mRNA / DNA directly to CF patients' lungs. 🦠 Marker Therapeutics, Inc. received $2 million grant from the NIH to support a Phase 1 study of MT-601. 🤑 𝗣𝗨𝗕𝗟𝗜𝗖 𝗢𝗙𝗙𝗘𝗥𝗜𝗡𝗚 🤑 🦠 Artiva Biotherapeutics raised $167 million in an IPO centered around the promise of donor-derived cell therapies for autoimmune diseases. 🧬 Precigen raised ~$31.4 million to advance PRGN-2012 to regulatory approval and commercial readiness. 🦠 TC BioPharm closed a $2 million direct public offering to support a clinical trial for relapsed / refractory AML. 🤑 𝗣𝗢𝗦𝗧-𝗜𝗣𝗢 𝗘𝗤𝗨𝗜𝗧𝗬 🤑 🦠 Cartesian Therapeutics announced a $130 million PIPE financing deal to fund pipeline programs. 🤑 𝗣𝗥𝗜𝗩𝗔𝗧𝗘 𝗘𝗤𝗨𝗜𝗧𝗬 🤑 🦠 SmartCella Holding AB raised EUR 50 million to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. 🤑 𝗦𝗛𝗔𝗥𝗘 𝗢𝗙𝗙𝗘𝗥𝗜𝗡𝗚 🤑 🧬 MeiraGTx announced a $50 million share offering to support the development of their gene therapies. #mCGT #advancedtherapies #ATMP #funding #investment

49

4 Comments

Why Gilead Sciences and Arcellx Anito-cel's data shows Promise in Multiple Myeloma Therapy Innovative Safety Profile: Early clinical data suggest anito-cel offers a reassuring safety advantage, with no reported cases of Parkinsonism, cranial nerve palsies, or Guillain-Barré syndrome—potentially addressing critical quality-of-life concerns. Encouraging Efficacy: With a 97% response rate and a median progression-free survival of 30.2 months in Phase 1, anito-cel demonstrates strong potential as an effective treatment option in heavily pretreated multiple myeloma patients. Cutting-Edge Technology: Anito-cel’s unique D-Domain binding technology may contribute to its promising safety and efficacy, reflecting innovation in CAR-T therapy design. #CellTherapy #MultipleMyeloma #InnovationInHealthcare #CAR_T #advancedtherapies #biotech #biotechnology #lifesciences #Data #ASH2024 https://lnkd.in/eCmJ_vP3

26

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs RATIONALE Cell-based therapies could in principle be programmed to locally protect tissues from immune attack without systemic immunosuppression. To generate targeted suppressor cells, one might redirect endogenous cells, such as regulatory T cells or myeloid suppressor cells, to recognize sites of disease. In this study, however, we took a reconstitution approach of engineering conventional CD4+ T cells to function as synthetic suppressor cells, allowing us to systematically explore the fundamental requirements for immune suppression. RESULTS We designed synthetic suppressor T cells by engineering conventional CD4+ T cells with synthetic Notch (synNotch) regulatory circuits that drive antigen-induced production of custom anti-inflammatory payloads. Exploring a diverse library of multiagent suppression programs, we found that the most effective synthetic suppressor T cells for blocking cytotoxic CD4+ and CD8+ T cell activity combine both anti-inflammatory factors [e.g., interleukin-10 (IL-10), transforming growth factor–β1 (TGFβ1), programmed death ligand 1 (PD-L1)] and sinks for proinflammatory cytokines (e.g., IL-2 receptor subunit CD25), mimicking the overall evolutionary design of regulatory T cells. Suppression programs that induce CD25 drove both IL-2 consumption and preferential expansion of suppressor T cells, creating a positive feedback loop that further increased local anti-inflammatory payload production. Synthetic suppressor T cells locally blocked the strong cytotoxicity induced by chimeric antigen receptor (CAR) T cells in vivo. We demonstrated that such engineered suppressor T cells can be used to generate “NOT gate” antitumor killing circuits, where suppressor T cells protect specific tissues from CAR T cell cross-reaction without compromising on-target, antitumor activity. Synthetic suppressor T cells also locally protected transplants from cytotoxic T cell rejection in a mouse model of pancreatic islet transplantation, maintaining endocrine activity of the transplants without systemic immunosuppression. https://lnkd.in/gZrbgBTA

17

Intellia Therapeutics, Inc.’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis - BioSpace Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s Amvuttra. Intellia Therapeutics over the weekend released Phase I data for its investigational gene editor nexiguran ziclumeran, touting promising biomarker improvements in patients with transthyretin amyloidosis, pointing to the disease-modifying potential of the therapy. The Phase I results, presented Saturday at the American Heart Association’s 2024 Scientific Sessions in Chicago, showed that nex-z resulted in “rapid, deep and durable” reductions in serum levels of TTR, according to Intellia’s press announcement. In patients with transthyretin amyloidosis (ATTR) with cardiomyopathy, a single dose of nex-z led to a sustained decrease in serum TTR level, with the mean reduction hitting 90% at 12 months. All 11 patients with follow-up data through 24 months were able to maintain response to nex-z, showing no signs of waning treatment effect over time. According to Intellia, consistent reductions in serum TTR could potentially suppress the formation of amyloid, in turn allowing for amyloid clearance and symptomatic improvement in patients. In this vein, the Phase I study also detected signals of disease-modifying effects for cardiac disease, with patients at 12 months showing signs of stabilization or improvement—despite many being enrolled with advanced or severe disease. At 12 months, 81% of treated patients showed stability or improvement in N-terminal prohormone of brain natriuretic peptide levels, an indicator of heart problems. Meanwhile, 94% and 77% of patients saw stable or better high-sensitivity Troponin T levels and six-minute walk test results, respectively. All three cardiac disease markers either stabilized or improved in 66% of patients. https://lnkd.in/gGwp6vb8

5

Contineum Therapeutics has launched a Phase 1b positron emission tomography (PET) trial for PIPE-791, a new brain-penetrant, small molecule antagonist targeting the lysophosphatidic acid 1 receptor (LPA1R). This open-label trial, conducted at a single center, aims to establish a correlation between pharmacokinetics and receptor occupancy in healthy volunteers, as well as individuals with idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS). Anticipated to deliver top-line results in Q2 2025, the study will utilize a PET tracer for the LPA1 receptor to assess receptor occupancy in the brain and lungs. The trial's significance lies in its potential impact on the treatment landscape for IPF and PrMS. Current therapeutic options for these conditions are limited, often resulting in disease progression despite available treatments. PIPE-791 introduces a new mechanism by targeting the LPA1 receptor, known for its involvement in fibrosis and neuroinflammation, the primary drivers of IPF and PrMS, respectively. By demonstrating target engagement in these disease contexts, the trial could pave the way for a fresh therapeutic strategy, potentially addressing unmet needs in patients battling these challenging conditions. Designed to establish a vital connection between the drug's pharmacokinetics and pharmacodynamics, the Phase 1b trial will evaluate how PIPE-791 concentrations in the body correspond to LPA1 receptor occupancy in the brain and lungs. This data is crucial for determining the optimal dosage of PIPE-791 for future efficacy trials in IPF and PrMS. Successful validation of target engagement through receptor occupancy in patients with these diseases will bolster the therapeutic promise of PIPE-791 and guide the formulation of subsequent clinical trials. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/dVFGqq9Q Carmine Stengone Julie Iwashita

1

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Another great read! Comprehensive analysis and recommendations for CAR-T flow cytometry workflows. Ranging from a description of the available controls, to the challenges in assay development and the rigor that is necessary to release a functional safe and validated flow cytometry assay. As stewards of science, we must always strive for transparency and perseverance of best practices. Again, this is a must-have for any an all CAR-T biotechs that use flow cytometry!! and its open access!!! #flow #flowcytometry #cart #immunology #assayvalidation #assaydevelopment #celltherapy https://lnkd.in/eiPPy2G6

27